Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513526 · ClinicalTrials.gov registry record · Phase 2
Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
A Phase 2 study, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT00513526: Completed Phase 2 study, sponsored by AIDS Malignancy Consortium.
NCT00513526 is a Phase 2 study that has completed, run by AIDS Malignancy Consortium. The registered enrollment target is 112 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00513526, a Phase 2 study, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells. PURPOSE: This phase II trial is studying the side effects and how well human papillomavirus vaccine therapy works in treating men with HIV-1 infection.
Primary Outcome
Occurrence of grade 3+ adverse events that are at least probably and definitely related to the vaccine
Interventions
- BIOLOGICAL Gardasil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
What the finished NCT00513526 record still lists
NCT00513526 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% lower).
The record links to 0 conditions, and to 1 intervention - of which Gardasil is the first listed.
NCT00513526 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00513526 about?
NCT00513526 is a clinical study titled "Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection". RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells. PURPOSE: This phase II trial is studying the side effects and how well human papillomavirus vaccine therapy works in treating men with HIV-1 infection.
What is the current status of trial NCT00513526?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2007-11. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00513526?
The interventions under investigation include: Gardasil (BIOLOGICAL).
Who is sponsoring clinical trial NCT00513526?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00513526's enrollment target sits among peer trials
112 631st of 2000 higher than 1,369 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia